132 related articles for article (PubMed ID: 2276311)
1. Steady-state pattern electroretinogram following long term unilateral administration of timolol to ocular hypertensive subjects.
Nesher R; Trick GL; Kass MA; Gordon MO
Doc Ophthalmol; 1990 Sep; 75(2):101-9. PubMed ID: 2276311
[TBL] [Abstract][Full Text] [Related]
2. Pattern electroretinogram in treated ocular hypertension: a cross-sectional study after timolol maleate therapy.
Colotto A; Salgarello T; Giudiceandrea A; De Luca LA; Coppè A; Buzzonetti L; Falsini B
Ophthalmic Res; 1995; 27(3):168-77. PubMed ID: 8538995
[TBL] [Abstract][Full Text] [Related]
3. Transiently raised intraocular pressure reveals pattern electroretinogram losses in ocular hypertension.
Colotto A; Falsini B; Salgarello T; Buzzonetti L; Cermola S; Porrello G
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2663-70. PubMed ID: 8977480
[TBL] [Abstract][Full Text] [Related]
4. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial.
Kass MA
Trans Am Ophthalmol Soc; 1989; 87():598-618. PubMed ID: 2562546
[TBL] [Abstract][Full Text] [Related]
5. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study.
Ventura LM; Porciatti V
Ophthalmology; 2005 Jan; 112(1):20-7. PubMed ID: 15629815
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of retinal ganglion cell function after intraocular pressure reduction measured by pattern electroretinogram in patients with primary open-angle glaucoma.
Karaśkiewicz J; Penkala K; Mularczyk M; Lubiński W
Doc Ophthalmol; 2017 Apr; 134(2):89-97. PubMed ID: 28176172
[TBL] [Abstract][Full Text] [Related]
7. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma.
Parisi V; Miglior S; Manni G; Centofanti M; Bucci MG
Ophthalmology; 2006 Feb; 113(2):216-28. PubMed ID: 16406535
[TBL] [Abstract][Full Text] [Related]
8. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
9. The pattern-electroretinogram in glaucoma and ocular hypertension. A cross-sectional and longitudinal study.
Pfeiffer N; Bach M
Ger J Ophthalmol; 1992; 1(1):35-40. PubMed ID: 1477616
[TBL] [Abstract][Full Text] [Related]
10. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial.
Kass MA; Gordon MO; Hoff MR; Parkinson JM; Kolker AE; Hart WM; Becker B
Arch Ophthalmol; 1989 Nov; 107(11):1590-8. PubMed ID: 2818278
[TBL] [Abstract][Full Text] [Related]
11. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
12. Pattern ERG as an early glaucoma indicator in ocular hypertension: a long-term, prospective study.
Bach M; Unsoeld AS; Philippin H; Staubach F; Maier P; Walter HS; Bomer TG; Funk J
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4881-7. PubMed ID: 17065502
[TBL] [Abstract][Full Text] [Related]
13. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
14. Long-term drift and timolol therapy: possible role for pulsed therapy.
Batterbury M; Harding SP; Wong D
Int Ophthalmol; 1992 Sep; 16(4-5):321-4. PubMed ID: 1428566
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of the pattern electroretinogram in high-risk ocular hypertension.
Pfeiffer N; Tillmon B; Bach M
Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1710-5. PubMed ID: 8473110
[TBL] [Abstract][Full Text] [Related]
16. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
17. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.
Rácz P; Ruzsonyi MR; Nagy ZT; Gaygi Z; Bito LZ
Arch Ophthalmol; 1996 Mar; 114(3):268-73. PubMed ID: 8600885
[TBL] [Abstract][Full Text] [Related]
18. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
19. Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension.
Bengtsson B; Heijl A
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2839-42. PubMed ID: 11687526
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
